Kenneth C. Anderson M.d.

Biography

Dr. Kenneth C. Anderson, also known as Ken, M.D. has been the Chief of Division of Hematologic Neoplasia at the Dana-Farber Cancer Institute since 2002. Dr. Anderson has been Councilor at American Society Of Hematology since January 2010. He is a Scientific Founder of Acetylon Pharmaceuticals, Inc. and OncoPep, Inc. He is the Founder of C4 Therapeutics, Inc. He has been an Attending Physician at the Bone Marrow Transplantation Service at Brigham and Women's Hospital since 1997. Dr. Anderson has been Vice Chairman of the Joint Program in Transfusion Medicine at Harvard Medical School since 2000. He serves as a Member of Managing Myeloma Advisory Board at MediCom Worldwide, Inc. He has been a Director of the Jerome Lipper Multiple Myeloma Center of the Dana-Farber Cancer Institute since 2000 and the Associate Medical Director of Brigham and Women's Hospital Blood Bank since 1998. He serves as a Member of Scientific Advisory Board and Director at Acetylon Pharmaceuticals, Inc. and Gilead Sciences Inc. He serves as a Member of Clinical Advisory Board at Nereus Pharmaceuticals, Inc. He serves as a Member of Scientific Advisory Board at Frequency Therapeutics, Inc. He serves as a Member of the Scientific Advisory Board at Signal Genetics, Inc. He serves as a Director and Member of Scientific Advisory Board at OncoPep, Inc. He has been Member of Clinical & Scientific Advisory Board at 3D Signatures Inc. since November 2016. He has been Member of Scientific Advisory Board at C4 Therapeutics, Inc. since November 17, 2016. He has been a Director of American Association of Cancer Research since April 2, 2012. He served as a Member of Clinical Advisory Board at Avalon Pharmaceuticals, Inc. since January 2007. He served as an Independent Director of Gentium S.p.a. since June 2005 and also served as a Member of its Scientific Advisory Board. He served as a Member of Scientific Advisory Board at Infinity Pharmaceuticals, Inc. He served as a Member of Scientific Advisory Board at MannKind Corporation. He served as a Member of Scientific Advisory Board at Callisto Pharmaceuticals, Inc. (formerly, Webtronics Inc.) since August 5, 2003. He is a Member of 11 medical and scientific societies and serves on the editorial boards of 11 medical and scientific journals. He has been a Professor at the Dana-Farber Cancer Institute, Cancer Research and Clinical Care since 1980. Dr. Anderson has been a Professor of Medicine at Harvard Medical School since 2000 and a Kraft Family Professor of Medicine since 2002. He is a Leader in the discovery of pathways that regulate growth of multiple myeloma cells and in the testing in clinical trials of drugs that disrupt these pathways. He is a well recognized Leader in multiple myeloma research and clinical drug development. Dr. Anderson trained in internal medicine at John's Hopkins Hospital and completed hematology, medical oncology and tumor immunology training at DFCI. Dr. Anderson graduated from Johns Hopkins Medical School, trained in internal medicine at Johns Hopkins Hospital and completed hematology, medical oncology and tumor immunology training at Dana-Farber Cancer Institute. He received a B.A., summa cum laude from Boston University in 1973, an M.D. from Johns Hopkins University School of Medicine in 1977 and an M.A. from Harvard University in 2000.

Research Interest

 Entrepreneurship & Organization Management